Merck & Company (MRK)

$119.56 +3.72 (3.21%)
Market Cap 273.69B
Revenue (ttm) 64.17B
Net Income (ttm) 17.12B
EPS (ttm) N/A
PE Ratio 12.52
Forward PE 17.46
Profit Margin 26.68%
Debt to Equity Ratio 0.77
Volume 13,941,516
Avg Vol 14,205,224
Day's Range N/A - N/A
Shares Out 2.48B
Stochastic %K 79%
Beta 0.29
Analysts Strong Sell
Price Target $115.12

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as liv...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
FlaMeZ907
FlaMeZ907 Feb. 4 at 8:09 PM
$MRK Waited 5 hours just to get $2 out of this Jerck & Company. 💩 Let's review... Yesterday they stole $700 in 5 minutes with my IBM calls. Then I waited all day today just to get a measly $70 back. That's a 1:10 ratio on wins/losses. I think I'm gonna have to call it quits here. Between the illegal bid/ask fills that Sob is doing, assigning contracts 2 weeks before expiration and now being a JP Bag with the little trades I do win... The lawyer said to pull my money out before we sue anyway. After the Floppers won last night and I hit that Huff'n'Puff jackpot, I think it's obvious whose paying the bills.
0 · Reply
erevnon
erevnon Feb. 4 at 7:20 PM
Citigroup maintains Merck & Co $MRK at Neutral and raises the price target from $115 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 4 at 6:25 PM
$LLY $NVO $JNJ $GSK $MRK annual revenues and net income '21-'25.
0 · Reply
erevnon
erevnon Feb. 4 at 6:17 PM
Cantor Fitzgerald maintains Merck & Co $MRK at Neutral and raises the price target from $116 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Cedenmo
Cedenmo Feb. 4 at 5:33 PM
$BMY $MRK $PFE Fantastic movement for my “Big 3.”
0 · Reply
StaceyBeasley634
StaceyBeasley634 Feb. 4 at 5:28 PM
$MRK remains supported by its pharmaceutical pipeline and global healthcare demand. ALDS completed a scalable platform rebuild designed to drive sustained sales growth and improved customer experience. https://finance.yahoo.com/news/applife-digital-solutions-inc-completes-153500313.html
0 · Reply
T_L808
T_L808 Feb. 4 at 5:16 PM
$MRK boring alpha
0 · Reply
goinbananas
goinbananas Feb. 4 at 5:13 PM
$MRK burning red hot 🔥 had to take 60% off the table today. Still keeping 40% as the PE is still pretty low! $PPH $QQQ $SPY
0 · Reply
OptionSamurai
OptionSamurai Feb. 4 at 4:37 PM
$MRK appears in our Dividend Capture scan. The idea is to buy shares + sell call to enjoy premium and the dividend. ☑ The Fundamental score is 8 ☑ Growth score is 9 ☑ Dividend date 16-Mar-26 ☑ IV Percentile is 55.2% Covered Call 115.0, 20-Mar-26: 📈 An annualized return of 28.3% 📉 The breakeven point is 4.0% 👉 See more results & customize here: https://bit.ly/3lR1xIP
0 · Reply
Turbofueled
Turbofueled Feb. 4 at 4:25 PM
$LEXX setting up!! $LEXX is Coming! Reduction in Side Effects being the biggest challenge!! $NVO $LLY $MRK https://www.techtarget.com/pharmalifesciences/news/366638713/GLP-1-therapies-set-to-top-global-drug-sales-in-2026
0 · Reply
Latest News on MRK
CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

Feb 4, 2026, 8:15 AM EST - 6 hours ago

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

MRNA

Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 1:30 PM EST - 1 day ago

Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 1 day ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

PFE

Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow

Feb 3, 2026, 11:06 AM EST - 1 day ago

Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow

Merck tops Q4 earnings expectations but issues weaker 2026 outlook

Feb 3, 2026, 7:14 AM EST - 1 day ago

Merck tops Q4 earnings expectations but issues weaker 2026 outlook

Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year

Feb 3, 2026, 6:55 AM EST - 1 day ago

Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year

Merck Earnings Top Estimates. Why the Stock Is Falling.

Feb 3, 2026, 6:48 AM EST - 1 day ago

Merck Earnings Top Estimates. Why the Stock Is Falling.

Merck Expects Slower Earnings Growth As It Spends on Acquisitions

Feb 3, 2026, 6:38 AM EST - 1 day ago

Merck Expects Slower Earnings Growth As It Spends on Acquisitions

Merck forecasts 2026 sales below estimates on patent losses

Feb 3, 2026, 6:34 AM EST - 1 day ago

Merck forecasts 2026 sales below estimates on patent losses

Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Feb 3, 2026, 6:31 AM EST - 1 day ago

Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

Feb 3, 2026, 6:30 AM EST - 1 day ago

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

5 Stocks That Could Outperform Even in a Pullback

Jan 30, 2026, 1:09 PM EST - 5 days ago

5 Stocks That Could Outperform Even in a Pullback

HON MSFT PG

What's Fueling The Rally In Merck Stock?

Jan 28, 2026, 11:10 AM EST - 7 days ago

What's Fueling The Rally In Merck Stock?

Merck Announces Second-Quarter 2026 Dividend

Jan 27, 2026, 3:07 PM EST - 7 days ago

Merck Announces Second-Quarter 2026 Dividend

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

Jan 26, 2026, 10:30 PM EST - 8 days ago

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

A ADBE AXP B C CBOE CHKP

Overlooked Stock: RVMD Sells After MRK Turns Away

Jan 26, 2026, 4:30 PM EST - 8 days ago

Overlooked Stock: RVMD Sells After MRK Turns Away

RVMD

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse

Jan 26, 2026, 6:01 AM EST - 9 days ago

Revolution Medicines Stock Sinks After Merck Deal Talks Collapse

RVMD

Merck no longer in talks to buy Revolution Medicines, WSJ reports

Jan 25, 2026, 3:27 PM EST - 9 days ago

Merck no longer in talks to buy Revolution Medicines, WSJ reports

RVMD

Merck No Longer in Talks to Buy Revolution Medicines

Jan 25, 2026, 2:30 PM EST - 10 days ago

Merck No Longer in Talks to Buy Revolution Medicines

RVMD

Top 10 Dividend Stocks For Uncertain Times

Jan 22, 2026, 5:00 AM EST - 13 days ago

Top 10 Dividend Stocks For Uncertain Times

BMY CDP DRH HST LNC PINE PSX

Merck partners with global health coalition to develop affordable Ebola vaccine

Jan 21, 2026, 11:01 AM EST - 14 days ago

Merck partners with global health coalition to develop affordable Ebola vaccine

Moderna, Merck Report Positive Results From Cancer-Vaccine Study

Jan 20, 2026, 6:58 AM EST - 15 days ago

Moderna, Merck Report Positive Results From Cancer-Vaccine Study

MRNA

Moderna, Merck's skin cancer vaccine shows sustained benefit after five years

Jan 20, 2026, 6:25 AM EST - 15 days ago

Moderna, Merck's skin cancer vaccine shows sustained benefit after five years

MRNA

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

Jan 20, 2026, 6:00 AM EST - 15 days ago

Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

MRNA

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Jan 16, 2026, 8:40 AM EST - 19 days ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

CVS GSK

Is Merck Stock A Trap At $110?

Jan 15, 2026, 9:10 AM EST - 20 days ago

Is Merck Stock A Trap At $110?

Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 10:25 PM EST - 22 days ago

Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s

Jan 12, 2026, 8:01 PM EST - 22 days ago

Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

Jan 11, 2026, 7:40 AM EST - 24 days ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

AMGN CVX HD JNJ KO NKE PG

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

Jan 10, 2026, 9:52 AM EST - 25 days ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

AMGN CRM DIS HD HON JNJ KO

Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion

Jan 9, 2026, 2:58 PM EST - 26 days ago

Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion

RVMD

Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck

Jan 9, 2026, 1:25 PM EST - 26 days ago

Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck

FDX SLB

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 26 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN AZN BMY LLY NVO PFE

Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list

Jan 8, 2026, 5:53 PM EST - 26 days ago

Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list

Merck in talks to buy biotech Revolution Medicines, FT reports

Jan 8, 2026, 3:56 PM EST - 26 days ago

Merck in talks to buy biotech Revolution Medicines, FT reports

RVMD

Cramer's Stop Trading: Merck

Jan 8, 2026, 10:31 AM EST - 27 days ago

Cramer's Stop Trading: Merck

Merck: Fundamentals Amplified By A Momentum Breakout

Jan 8, 2026, 8:00 AM EST - 27 days ago

Merck: Fundamentals Amplified By A Momentum Breakout

The Big 3: XRT, MRK, CAT

Jan 7, 2026, 1:00 PM EST - 4 weeks ago

The Big 3: XRT, MRK, CAT

XRT CAT

Merck could lose up to $630 million in revenue after CDC changes HPV vaccine recommendation

Jan 7, 2026, 12:36 PM EST - 4 weeks ago

Merck could lose up to $630 million in revenue after CDC changes HPV vaccine recommendation

Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO

Jan 7, 2026, 8:01 AM EST - 4 weeks ago

Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO

Quant Q&A With Steven Cress

Jan 7, 2026, 7:00 AM EST - 4 weeks ago

Quant Q&A With Steven Cress

CLS CRDO ET FIX PFE

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Jan 7, 2026, 6:50 AM EST - 4 weeks ago

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Merck to Complete Acquisition of Cidara Therapeutics

Jan 7, 2026, 6:45 AM EST - 4 weeks ago

Merck to Complete Acquisition of Cidara Therapeutics

Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

Jan 7, 2026, 6:30 AM EST - 4 weeks ago

Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 6:45 AM EST - 4 weeks ago

Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Top 10 High-Yield Dividend Stocks For January 2026

Jan 3, 2026, 1:20 AM EST - 4 weeks ago

Top 10 High-Yield Dividend Stocks For January 2026

ADP CMCSA CNS EOG KDP MKC NEE

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

Jan 2, 2026, 5:06 PM EST - 4 weeks ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

AMGN CVX HD JNJ KO NKE PG

Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Jan 1, 2026, 3:11 AM EST - 4 weeks ago

Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Merck: Framework For Success

Jan 1, 2026, 2:57 AM EST - 4 weeks ago

Merck: Framework For Success

Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis

Dec 30, 2025, 12:03 PM EST - 5 weeks ago

Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis

FlaMeZ907
FlaMeZ907 Feb. 4 at 8:09 PM
$MRK Waited 5 hours just to get $2 out of this Jerck & Company. 💩 Let's review... Yesterday they stole $700 in 5 minutes with my IBM calls. Then I waited all day today just to get a measly $70 back. That's a 1:10 ratio on wins/losses. I think I'm gonna have to call it quits here. Between the illegal bid/ask fills that Sob is doing, assigning contracts 2 weeks before expiration and now being a JP Bag with the little trades I do win... The lawyer said to pull my money out before we sue anyway. After the Floppers won last night and I hit that Huff'n'Puff jackpot, I think it's obvious whose paying the bills.
0 · Reply
erevnon
erevnon Feb. 4 at 7:20 PM
Citigroup maintains Merck & Co $MRK at Neutral and raises the price target from $115 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 4 at 6:25 PM
$LLY $NVO $JNJ $GSK $MRK annual revenues and net income '21-'25.
0 · Reply
erevnon
erevnon Feb. 4 at 6:17 PM
Cantor Fitzgerald maintains Merck & Co $MRK at Neutral and raises the price target from $116 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Cedenmo
Cedenmo Feb. 4 at 5:33 PM
$BMY $MRK $PFE Fantastic movement for my “Big 3.”
0 · Reply
StaceyBeasley634
StaceyBeasley634 Feb. 4 at 5:28 PM
$MRK remains supported by its pharmaceutical pipeline and global healthcare demand. ALDS completed a scalable platform rebuild designed to drive sustained sales growth and improved customer experience. https://finance.yahoo.com/news/applife-digital-solutions-inc-completes-153500313.html
0 · Reply
T_L808
T_L808 Feb. 4 at 5:16 PM
$MRK boring alpha
0 · Reply
goinbananas
goinbananas Feb. 4 at 5:13 PM
$MRK burning red hot 🔥 had to take 60% off the table today. Still keeping 40% as the PE is still pretty low! $PPH $QQQ $SPY
0 · Reply
OptionSamurai
OptionSamurai Feb. 4 at 4:37 PM
$MRK appears in our Dividend Capture scan. The idea is to buy shares + sell call to enjoy premium and the dividend. ☑ The Fundamental score is 8 ☑ Growth score is 9 ☑ Dividend date 16-Mar-26 ☑ IV Percentile is 55.2% Covered Call 115.0, 20-Mar-26: 📈 An annualized return of 28.3% 📉 The breakeven point is 4.0% 👉 See more results & customize here: https://bit.ly/3lR1xIP
0 · Reply
Turbofueled
Turbofueled Feb. 4 at 4:25 PM
$LEXX setting up!! $LEXX is Coming! Reduction in Side Effects being the biggest challenge!! $NVO $LLY $MRK https://www.techtarget.com/pharmalifesciences/news/366638713/GLP-1-therapies-set-to-top-global-drug-sales-in-2026
0 · Reply
FlaMeZ907
FlaMeZ907 Feb. 4 at 3:58 PM
$MRK Merk Merk Merk. When no one is talking about it other than the bots and spammers who tag 20 companies per post, then you know I'm the only one actually trading it, LOL! 🤡 Let's get that $250 per share by 2:50pm.
0 · Reply
erevnon
erevnon Feb. 4 at 3:30 PM
Wells Fargo maintains Merck & Co $MRK at Overweight and raises the price target from $125 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Fingerlickengood
Fingerlickengood Feb. 4 at 3:26 PM
$CDXS $MRK https://www.fiercepharma.com/pharma/merck-confident-post-keytruda-future-70b-opportunity-next-decade-growth-drivers
0 · Reply
KPLongInvestor
KPLongInvestor Feb. 4 at 2:51 PM
$MRK great run. pipeline continues to look better
0 · Reply
taxplanr
taxplanr Feb. 4 at 2:51 PM
Ivermectin and Mebendazole make patient Cancer Free $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-e88?utm_source=post-email-title&publication_id=1385328&post_id=186831541&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
RonIsWrong
RonIsWrong Feb. 4 at 2:40 PM
$MRK What a move!!! I sold half of my calls yesterday at $18 from $3.47! Big thanks to @AboveTheHorizon for that play.
0 · Reply
taxplanr
taxplanr Feb. 4 at 2:37 PM
$ABBV declining oncology sales huh? $BNTX $MRNA $BMY $MRK Cancer patients are declining chemo for Ivermectin Fenbendazole Menbendazole CBD and just about anything else And doing better
0 · Reply
InsuranceSalesman
InsuranceSalesman Feb. 4 at 1:46 PM
$MLTX $LILY.X $MRK and $ABBV all reported and beat estimates this week. Flush with cash and nothing to do with it!
1 · Reply
NasdaqPulse
NasdaqPulse Feb. 4 at 1:33 PM
$MRK | Business Development Update • BD remains a high priority — mgmt actively pursuing transactions where science & value align • “Sweet spot” for deals: up to $15B, but open to larger deals if fundamentals & science justify it • Focused on value creation through strategic acquisitions & partnerships Takeaway: MRK is poised to deploy capital intelligently, targeting deals that drive growth and long-term shareholder value.
0 · Reply
mikesterz7
mikesterz7 Feb. 4 at 12:09 PM
$MRK Scotiabank lifted its Merck target to $136 and kept an ‘Outperform’ rating, implying a 17% upside.
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 4 at 7:13 AM
How Merck Is Preparing For The Patent Cliff Of Its Blockbuster Cancer Drug Keytruda $MRK https://stocktwits.com/news/equity/markets/how-merck-is-preparing-for-the-patent-cliff-of-its-blockbuster-cancer-drug-keytruda/cZbSrK6R4Zd
0 · Reply
Dilly_Due
Dilly_Due Feb. 4 at 5:20 AM
$MRK $PFE $JNJ $VXRT $SNY Folks. How long are you gonna let the holy grail sit? Make the move. Make an offer. Start the bidding! The winner captures $40 bil. in future annual revenue with much upside. Just my humble opinion. Do your own DD. Very, very, very....
0 · Reply